Spark Trails BioMarin In Hemophilia Gene Therapy Race – Forbes
Forbes |
Spark Trails BioMarin In Hemophilia Gene Therapy Race
Forbes Spark Therapeutics, the company likely to launch the first gene therapy in the U.S., is presenting data on both of its gene therapies for hemophilia this morning at the annual meeting of the American Society of Hematology in Atlanta. The most closely … #ASH17: Spark triggers a backlash as early hemophilia A gene therapy data looks shaky BioMarin Pharma (BMRN) Highlights 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for … Spark Therapeutics Presents Preliminary Data on Investigational SPK-8011 Phase 1/2 Dose-escalation Clinical Trial in … |
